Seaport Therapeutics jumps over 20% on Nasdaq debut as former Karuna team outlines CNS research plans
read at Endpoints ↗Positive
Seaport Therapeutics began trading on Nasdaq on May 1, 2026, ringing the opening bell. Its shares surged more than 20% on the first day.
The company’s leadership, including the CEO and CSO, highlighted that much of the team comes from Karuna Therapeutics, bringing experience in central nervous system drug development.
They discussed how lessons learned at Karuna will shape Seaport’s approach to CNS research, emphasizing innovative strategies and a focus on advancing pipeline candidates.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Q&A: Seaport CEO and CSO on learning from Karuna and the future of CNS research”
read at Endpoints ↗100 words · retrieved May 1
comments(0)
5-min edit window · permanent after that